ep beat tax despit pharmedium nois guid oi tax
expect revenu ep w/ st guidanc updat rais tax reform underli consist
histor perform last yr ep qs move
quick take post mix first quarter sizeabl ep beat tax accompani guidanc
increas primarili due tax howev sever key busi unit under-perform name pharmedium lash
group oper incom growth actual lower term revenu segment offer reason
top-lin momentum margin om line slightli better forecast overal segment basi
distribut outperform despit pharmedium offlin dec howev disappoint lash mwi move
line interest expens help vs model tax notabl better allow major ep beat
 guidanc front revenu growth increas slightli ep taken overal tax rate
howev oper incom growth lower segment posit front guidanc actual
increas market assumpt inflat remain consist all-in type littl bit everyon
bear bull although would assum reaction today pend market slightli neg await
commentari confer call disappoint busi unit argu level comfort investor garner
respect base busi stabil well recoveri pharmmedium determin magnitud reaction
rais ep ex-th benefit lower tax rate oper guidanc
actual fell due lower contribut pharmediumaddit comment guidanc includ
revenu growth vs prior
 adj oper incom rang vs prior
 adj effect tax rate vs prior
free-cash-flow rais bn bn
drug price expect
brand inflat
 gener deflat
 similar contribut new gener launch
signific contribut biosimilar
abdc revenu grew acceler slightli telegraph
abdc impact reduc product pharmedium memphi facil follow fda inspect result
voluntarili suspend oper decemb
neg revenu grew y-o-i though oper incom fell weaker perform
lash group mwi partial off-set world courier
margin line expect quarter fell bp y-o-i
ep quarter benefit boost lower-than-expect tax rate
pleas see analyst certif import disclosur page report evercor isi affili seek busi
compani cover research report investor awar firm may conflict interest could affect object
report investor consid report singl factor make invest decis
inflat trajectori brand gener drug inclus earli view price increas seen jan
color key assumpt underli guid contribut particularli pharmedium benefit tax
updat view post announc potenti disrupt complex broadli barrier entri differ busi
feedback hd smith transact potenti synergi captur accret next twelv month
weak lash mwi potenti improv notabl oper margin
see pharmedium facil come back on-line inclus detail scope remedi measur
valuat price target base dcf methodolog contempl wacc termin
ebitda multipl equat perpetu growth rate pt translat ebitda vs
average price-to-earnings basi translat vs average
downsid risk potenti resumpt independ price war result materi margin degrad signific
profit pressur signific downtick sell-sid gener deflat without similar movement buy side margin result overal
compress increment soft pharmedium growth lessen inflat continu challeng relat revamp
qc process polit threat chang rx price methodolog gross net intens scrutini opioid curtail
distribut profit execut challeng onboard hd smith asset potenti leakag key independ custom
transit period inabl transit specialti contract long term new econom allow fair payment
articl articl
time dissemin februari et
analyst ross muken elizabeth anderson suzi yoon primarili respons prepar research report attest
follow view opinion render research report reflect person view subject compani issuer
part research analyst compens directli relat specif recommend view
report approv and/or distribut evercor group llc evercor group licens broker-deal regul
industri regulatori author finra intern strategi invest group uk limit isi uk authoris regul
unit kingdom financi conduct author institut sale trade research busi evercor group isi
uk collect oper global market brand name evercor isi evercor isi evercor group isi uk subsidiari
evercor partner inc evercor partner trademark logo servic mark shown report regist trademark
analyst associ respons prepar report receiv compens base variou factor includ evercor partner
total revenu portion gener affili invest bank transact evercor isi seek updat research
appropri variou regul may prevent happen certain instanc asid certain industri report publish
period basi larg major report publish irregular interv appropri analyst judgment
evercor isi gener prohibit analyst associ member household maintain financi interest secur
compani analyst area coverag except polici requir specif approv member complianc
depart ownership subject complianc applic regul disclosur evercor isi also prohibit analyst associ
member household serv offic director advisori board member employe compani analyst
report may includ tactic call describ near-term event catalyst affect subject compani market overal
expect short-term price impact equiti share subject compani tactic call separ analyst
long-term recommend outperform under-perform reflect stock forward expect return formal rate
may differ target price recommend reflect analyst long-term view
applic current disclosur regard subject compani cover report avail offic evercor isi
obtain write evercor group llc attn complianc fifth avenu floor new york ny
evercor partner affili respect director offic member employe may interest
qualifi hold issuer mention report evercor partner affili may busi relationship
compani mention report
addit inform secur financi instrument mention report avail upon request
evercor isi recommend base stock total forecast return next month total forecast return equal
expect percentag price return plu gross dividend yield divid stock coverag three primari rate categori
outperform total forecast return expect greater expect total return analyst coverag univers
total forecast return expect line expect total return analyst univers
under-perform total forecast return expect less expect total return analyst univers
coverag suspend rate target price remov pursuant evercor isi polici evercor act advisori
capac merger strateg transact involv compani certain circumst
rate suspend evercor isi suspend rate target price stock suffici fundament basi
determin legal regulatori polici constraint around publish rate target price previou rate target price
longer effect compani reli upon
prior octob coverag suspend rate suspend categori includ categori suspend
finra requir member use rate system term buy hold/neutr sell equat
rate categori purpos evercor isi rate distribut outperform
under-perform rate equat buy hold sell respect
prior march evercor isi recommend base stock total forecast return next month
buy total forecast return expect greater
hold total forecast return expect greater equal less equal
sell total forecast return expect less
octob evercor partner acquir intern strategi invest group llc isi group isi uk acquisit
transfer evercor group research sale trade busi isi group decemb combin research sale
trade busi transfer back evercor group intern reorgan sinc acquisit combin research sale
trade busi oper global market brand name evercor isi
isi group isi uk
prior octob rate system isi group llc isi uk base risk adjust total return
buy return
neutral return
cautiou return
disclosur purpos isi group isi uk rate view follow strong buy buy equat buy neutral equat hold
